ClinicalTrials.gg
RecruitingNCT05037370Updated Aug 14, 2025

CONTOURA vs WFO Ablation PRK & LASIK

An interventional study of Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation in Refractive Surgery, sponsored by 59th Medical Wing. Recruiting at 1 site in United States. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by 59th Medical Wing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2021, registered Aug 2021).
  • Started Apr 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Study summary

This is a prospective randomized contralateral double-masked study. Each patient will be randomized as to which eye undergoes wave-front optimized (WFO) vs. wave-front guided (WFG) during Photorefractive keratectomy (PRK) or Laser-assisted in situ Keratomileusis (LASIK) surgery to determine which ablation profile provides the best visual outcome.

Read the detailed description

In 2015, the FDA approved a new laser ablation profile for performing laser corneal refractive surgery. Multiple sophisticated profiles have been developed in an attempt to optimize visual outcomes and reduce post-operative lower and higher-order optical aberrations. Among these include wave-front optimized (WFO) and wave-front guided (WFG) ablation profiles. The former compensated for corneal curvature to reduce spherical aberration and the latter, a more complicated ablation profile, was designed to minimize specific aberrations in an individual eye. Topographic profiles have also been used for over 17 years. These profiles consider the shape of the anterior corneal surface. The newest such topographic ablation profile, Contoura Vision, is a topography guided (TG) profile that, based on over 22,000 curvature data points captured using the VARIO Topolyzer, individualizes the ablation pattern. For comparison, WFO uses a patient's estimated average corneal curvature alone to create an ablation pattern. The addition of the VARIO Topolyzer adds a significant increase of pre-operative patient preparation. Anecdotally, between 1-3hrs of additional technician hours are required to prepare a patient for the Contoura Vision TG ablation profile.

This will be a prospective randomized contralateral double-masked study. Patients will undergo the same standard of care preoperative evaluation and education as any other patient not enrolled in the study. The physician performing surgery will choose either LASIK or PRK, taking into account patient preference, preoperative data and overall clinical picture, ultimately choosing which is best for the patient. If a patient qualifies for both, the patient may choose either LASIK or PRK. Each patient will be randomized as to which eye undergoes a WFO treatment vs Contoura. At the time of surgery the patient will be blinded as to which eye receives which treatment, but the surgical team will not be blinded as to which procedure is performed. Post-operatively, the ophthalmic technicians and optometrists responsible for postoperative examinations (measurement of visual acuity, refractions, transcription of PRO's) will be blinded as to which eye underwent Contoura vs WFO. While treatments will vary, both have the same safety profile. Both involve sophisticated lasers to change the shape of the cornea to achieve the desired outcome. The variance comes in the type of pattern the laser uses to treat each individual. All post-operative care will be standard of care with medications being the same as if the patient were not enrolled in the study. Post-operative evaluations will take place at postoperative day 1, week 1, month 1, month 3, and month 6.

All data collected will be standard pre- and post-operative ophthalmic refractive surgery measurements. This includes a standard medical history, especially to include prior eye surgeries or diseases. Pre-operative measurements include vision assessments, contrast sensitivity, pre- and post-dilation as well as keratometry and axial length measurements. The Contoura requires a separate set of data collection via the VARIO topolyzer. Intraoperative data collected will include variables such as actual treatment outcomes and laser settings. Post-operative measurements will consist of many of the same measurements as those obtained preoperatively including uncorrected and corrected visual acuity, and refractive measurements. A symptoms-based questionnaire specific to corrective eye surgery (PROWL) will be given to patients before and after surgery during routine follow-ups. Each PROWL is specific to an individual eye, not specific to the surgery performed in each eye (i.e. the same PROWL questionnaire will be used regardless of whether the patient underwent PRK or LASIK). All PROWL data will be compared pre- and post-operatively and will be stratified based on surgery.

02

Conditions studied

  • Refractive Surgery

Keywords

  • Photorefractive Keratectomy (PRK)
  • Laser-assisted in situ Keratomileusis (LASIK)
  • Wave-Front Optimized (WFO)
  • Topography guided ablation
03

In context

Lead sponsor

59th Medical Wing is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet requirements for PRK or LASIK i.e., Stable \<= .5 D change MRSE)
  • DOD beneficiaries age 21-50 years
  • Local pts (w/i 60 mi) who will be in the area for at least 6 months post surgery
  • Willing to complete all required follow-up visits

Exclusion criteria

Exclusion Criteria:

  • No meeting requirements for PRK or LASIK
  • Desiring monovision treatment
  • Anisometropia >2D spherical equivalent
  • Prior ocular surgeries / trauma / problem
  • History of dry eyes
  • Hyperopia
  • Mixed astigmatism
  • Inability to capture VARIO topolyzer scans
  • Pregnant (or who plans to be within 6 months after surgery)
  • Breastfeeding any time during the study
  • History of herpetic disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    LASIK refractive surgery

    Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation

    Device: Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation

  • Experimental
    PRK refractive surgery

    Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation

    Device: Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation

Interventions

  • DeviceWave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation

    Patient will undergo PRK or LASIK using WFO ablation in one eye and TG ablation on contralateral eye

06

What researchers measure

Primary outcomes

  1. Post-operative refractive error

    The Post-Operative sphere equivalent refractive error for eyes undergoing Wave-Front Optimized (WFO) ablation vs Topography-guided ablation

    Time frame: 6 months post-surgery

Secondary outcomes

  1. Post-operative Uncorrected Visual Acuity

    The Post-Operative visual acuity for eyes undergoing Wave-Front Optimized (WFO) ablation vs Topography-guided ablation

    Time frame: 6 months post-surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2021
First posted
Sep 8, 2021
StartActual
Apr 22, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05037370
Lead sponsor
59th Medical Wing
Responsible party
Sponsor
First posted
Sep 8, 2021
Start date
Apr 22, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 14, 2025

Study contacts

JOSE E CAPO-APONTE, OD, PhD
Contact
Jose.E.CapoAponte.ctr@health.mil
210-292-2554
AMBER MARTIN
Contact
amber.l.martin38.ctr@health.mil
210-292-2483
CHARISMA B EVANGELISTA, MD
principal investigator · 59th Medical Wing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion